Geneseq Biosciences is a Melbourne based biotechnology company.
We are pioneering the development of new “liquid biopsy” tests to help doctors individualise cancer diagnostics & treatment options.
Our first test, Melaseq, is designed to accurately detect the genetic (microRNA) fingerprint of active melanoma in blood.
Melanoma is the most deadly form of skin cancer and is 3-4 more prevalent in Australia compared to the US and the UK. Early detection is the best defence against this aggressive form of cancer, however current methods are subjective, costly and can be inaccurate.
Our goal is to provide doctors with an additional tool to help diagnose melanoma in its early and most treatable stage, while reducing unnecessary biopsies and reducing healthcare costs.
- Characterisation and validation of Mel38; A multi-tissue microRNA signature of cutaneous melanoma.
- A plasma microRNA biomarker of melanoma as a personalised assessment of treatment response.
- Development and validation of a plasma-based melanoma biomarker suitable for clinical use.
More info: www.geneseq.com.au